Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Nektar’s call for calm backfires
In blaming bempegaldesleukin’s falling efficacy on poor manufacturing Nektar has alarmed investors even more.
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Novel drug approvals head for a down year
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Asco 2019 – the case for Nektar sweetens, slightly
Longer-term data bolster Nektar Therapeutics’ bempegaldesleukin, but things haven’t changed that much since its last disappointment.
Asco 2019 – Abstract drop fires the starting gun
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Licensing deal activity follows buyout market downwards
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
JP Morgan 2019 day two roundup – after the party a harsh reality
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.